全球血癌药物市场is anticipated to reach USD 55.6 billion by 2025 according to a new report published by Polaris Market Research. The report‘Blood Cancer Drugs Market [By Blood Cancer Type (Leukemia (Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia), Lymphoma (Hodgkin Lymphoma, Non-Hodgkin Lymphoma (B-Cell Lymphoma, T-Cell Lymphoma)), and Myeloma; By Drugs (Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), and Others); By Treatment Approaches (Chemotherapeutic, mAbs/Targeted Therapies, and Immunotherapeutic); By Region]: Market Size & Forecast, 2017 – 2025’provides insights on the current market scenario and the future prospects.
The demand for blood cancer drug is primarily driven by growing death incidences by blood cancer, and continuous innovation for developing novel treatments with the help of several ongoing clinical trials. Moreover, increasing research and development of biological and targeted therapies as treatment will spur the blood cancer drugs market during the upcoming period. However, the high price of drugs and the stringent government policies will limit the growth of blood cancer drugs market during the forecast period.
Most of the blood cancers start in the bone marrow, where blood is produced. In blood cancer the growth of normal blood cells is dislodged by the uncontrollable growth of abnormal blood cells. These cancerous cells prevent the blood from performing many of its functions. Hence, the existing treatments of blood cancer are being the foundation for developing the new drugs. The steady flow of the blood cancer drugs has created opportunity for research and development in the existing market. For instance, Amgen Inc. received approval for BLINCYTO in July 2017, which is used in treating B-cell precursor Acute Lymphoblastic leukemia. Similarly, European blood cancer drugs market witnessed the approvals of Gazyvaro, by Roche AG that is used in treating advanced follicular lymphoma. Also, novel technologies like CAR-T are likely to be launched this year.
全球血癌药物市场is segmented into blood cancer type, drugs and treatment approaches. On the basis of blood cancer type, the global blood cancer drugs market is segmented into leukemia, lymphoma and myeloma. The lymphoma segment is expected to drive the majority market of blood cancer drugs followed by leukemia. The global market of this segment is primarily driven by the increasing prevalence of lymphoma, and presence of effective treatments in the market. On the basis of drugs, the global blood cancer drugs market is further categorized into Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), and Others. This continuous innovation for treating various sub-types of blood cancers has led to the development of novel types of treatments. For instance, the combination of Revlimid and Velcade has emerged as the preferential drugs in trials for treating multiple myeloma.
Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below:
//m.ptlymt.com/idustry-analysis/global-blood-cancer-drugs-armet.
在治疗方法的基础上，全球血液癌症药物市场进一步分段为化学治疗，MAB /靶向疗法和免疫治疗性。由于市场中的各种化学治疗剂的可用性，预计将在血癌药物市场中占据较高的份额。此外，它们对全球治疗血癌和癌症患者数量越来越多的癌症患者的有效性已经为全世界的化学治疗药物提供了更多的需求。
Geographically, the global blood cancer drugs market is segmented into North America, Europe, Asia Pacific, and the rest of the world. North America dominates the blood cancer drugs market which is followed by Europe and Asia Pacific. Favorable reimbursement policies, surge in R&D investments of various companies, as well as the increase in the number of blood cancer treatments are some of the major factors responsible for the growth of North America’s blood cancer drugs market. Moreover, Asia-Pacific region has been identified as the lucrative market for the for blood cancer drugs due to increasing awareness of the use of these drugs, increased healthcare expenditure, and rising per capita disposable income. These are some of the major factors which are influencing the growth of the blood cancer drugs in Asia-pacific region.
在该行业中运营的领先公司包括Johnson＆Johnson Inc.，Amgen Inc.，Bayer Ag。，Pfizer，Inc。，Abbvie Inc.，Roche Holding AG。，Celgene Corporation，Astazeneca，Novartis AG，Glaxosmithkline Plc，Merck＆Co。，Inc.和Eli Lily＆Co。等。
Key Findings from the study suggest blood cancer drugs in the market are much innovative and manufacturers are progressively concentrating on innovation of combination drugs. Companies are in a stage of development of new drugs in order to provide novel treatments for blood cancer. The immunotherapy segment is anticipated to grow at a high growth rate over the forecast period. The growth of this segment is primarily driven by increased awareness for its use as an alternative and effective treatment for blood cancer. North America is presumed to dominate the global blood cancer drugs market over the forecast period. Asia Pacific region which shows signs of high growth potential owing to the booming economies of India, and China.
乐动体育软件最新版北极星市场研究分段全球blood cancer drugs market on the basis of type, drugs, treatment approaches and region:
血癌药物市场规模和预测，2017-2025血癌型
- 淋巴瘤
- 霍奇金淋巴瘤
- Non-Hodgkin Lymphoma
- B-cell Lymphoma
- 弥漫性大B细胞淋巴瘤
- Mantle Cell Lymphoma
- Burkitt淋巴瘤
- Central Nervous System Lymphoma
- T细胞淋巴瘤
- Precursor T-Lymphoblastic Lymphoma
- Peripheral T-Lymphoma
- B-cell Lymphoma
- 白血病
- 急性髓性白血病
- 慢性骨髓白血病
- 急性淋巴细胞白血病
- 慢性淋巴细胞白血病
- 骨髓瘤
- Multiple Myeloma
血癌药物市场规模和预测，2017-2025毒品
- Rituaxan/Mabthera (Rituximab)
- Gleevac / Glivec（伊马替尼）
- Revlimid（Lenalidomide）
- Velcade（Bortezomib）
- Tasigna (Nilotinib)
- Pomalyst（氯米德胺）
- Vidaza（亚辛酸）
- Kyprolis (Carfilzomib)
- Adcetris (Brentuximab Vedotin)
- Others
血癌药物市场规模和预测，2017-2025通过治疗方法
- Chemotherapeutic
- mAbs/Targeted Therapies
- Immunotherapeutic
Blood cancer drugs market Size and Forecast, 2017-2025 by Region
- North America
- U.S.
- 加拿大
- 欧洲
- 德国
- UK
- 法国
- Asia Pacific
- China
- Japan
- 印度
- 拉美
- 巴西
- 墨西哥
- Middle East & Africa